Program
TRL1068
Also written as “TRL1068, a human monoclonal antibody”.
Its studies are mostly in Nasal Polyps, led by Trellis Bioscience.
Furthest: phase 1, since Feb 12, 20213 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Trellis Bioscience | 31 open or running | phase 1since Feb 12, 2021 | Feb 12, 2021 | Dec 2026phase 1 · NCT07644195 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 12, 2021First study: phase 1 study in Prosthetic Joint InfectionFirst studyNCT04763759 · 15 enrolled · United States
- Apr 18, 2022Phase 1 study in Chronic Rhinosinusitis With Nasal PolypsNCT05355207 · 12 enrolled
- Jun 8, 2026Phase 1 study in Healthy VolunteerNCT07644195 · 14 planned · United States
Ahead
- Dec 2026Primary completion: phase 1 study in Healthy VolunteerNCT07644195
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07644195Healthy Volunteer · United States | 1 | Not yet recruiting | Dec 2026 | 14 |
| NCT05355207Chronic Rhinosinusitis With Nasal Polyps | 1 | UNKNOWN | Jan 2025 | 12 |
| NCT04763759Prosthetic Joint Infection · United States | 1 | Completed | Mar 13, 2024 | 15 |
How it is read
Names in the registry
- “TRL1068, a human monoclonal antibody”, 2 entries
- “TRL1068”, 1 entry
Conditions, from the studies’ own filings
- Nasal Polyps, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.